Trial Search Results

Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring

The purpose of doing this study is to see if continuous glucose monitoring can help people with type 1 diabetes who are sometimes unable to feel if they have a low blood glucose reading. For this study we will be using the Navigator Continuous Glucose Monitor. We think that your body may not have enough of a certain hormone that usually helps people know when they are going low. If you can keep from going low, we think there will be enough of that hormone to help you recognize the symptoms of a low before it happens.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: University of Colorado, Denver

Stanford Investigator(s):


  • Device: Navigator Continuous Glucose Monitor




Inclusion Criteria:

   1. Be at least 7 to 20 years old

   2. Have been diagnosed with type 1 diabetes for at least 1 year

   3. Report 2 or more episodes per week of asymptomatic hypoglycemia as determined by
   completion of the Hypoglycemia Awareness Questionnaire (HAQ) or as determined by

   4. HbA1c level < 10%

   5. Internet access for downloading continuous glucose monitoring (CGM), access to a
   compatible computer (Windows Vista is not compatible for downloading.)

   6. For females, you are not intending to become pregnant during the study

   7. No expectation that you will be moving out of the area for the duration of the study

Exclusion Criteria:

   1. The presence of a significant medical disorder (including epilepsy, or any cause of
   seizures other than hypoglycemia) that in the judgment of the Investigator will affect
   the wearing of the sensors or the completion of any aspect of the protocol

   2. Treatment with systemic or inhaled corticosteroids in the last six months

   3. Inpatient psychiatric treatment in the past six months for you or your primary

   4. Current use of oral/inhaled glucocorticoids or other medications, which in the
   judgment of the Investigator would be a contraindication to participation in the study

   5. Having two or more severe hypoglycemia episodes (seizure or loss of consciousness) in
   the six months prior to enrollment

   6. Having a severe hypoglycemic episode in the 30 days prior to enrollment

Ages Eligible for Study

7 Years - 20 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305